Antibody

Marengo Therapeutics Announces First Patient Dose in Phase 1/2 Clinical Trial of Its Novel TCR Vβ-Targeted Antibody Fusion Molecule STAR0602, in Cancer Patients Refractory to Anti-PD1 Therapy | DNA, RNA and cells

Marengo Therapeutics Announces First Patient Dose in Phase 1/2 Clinical Trial of Its Novel TCR Vβ-Targeted Antibody Fusion Molecule STAR0602, in Cancer Patients Refractory to Anti-PD1 Therapy details Category: DNA RNA and cells Posted on Saturday, January 28, 2023 at 6:33 pm Visit: 132 The START-001 study uses a tissue-agnostic biomarker-enriched approach to evaluate …

Marengo Therapeutics Announces First Patient Dose in Phase 1/2 Clinical Trial of Its Novel TCR Vβ-Targeted Antibody Fusion Molecule STAR0602, in Cancer Patients Refractory to Anti-PD1 Therapy | DNA, RNA and cells Read More »

Scientists have identified a new epitope at the furin cleavage site of the SARS-CoV-2 spike

Scientists have identified an immunogenic epitope at the furin cleavage site of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that induces a robust antibody response in patients with coronavirus disease 2019 (COVID-19). In his study published in the journal eBiomedicine, researchers also identified a monoclonal antibody that binds to this epitope and protects mice from …

Scientists have identified a new epitope at the furin cleavage site of the SARS-CoV-2 spike Read More »

JITC Publication on the Mechanism of Akes’ Ligufalimab (a CD47 Monoclonal Antibody) Shows Promising Antitumor Efficacy and a Favorable Safety Profile

HONG KONG, December 11, 2022 /PRNewswire/ — Akeso Inc. (9926. HK) (“Akeso”) announced today that the Journal for Immunotherapy of Cancer (JITC), a BMJ oncology journal, has published the mechanism of action of its Ligufalimab (AK117). The title of the article is “Ligufalimab, a novel non-hemagglutination-free anti-CD47 antibody that shows both monotherapy and combination antitumor …

JITC Publication on the Mechanism of Akes’ Ligufalimab (a CD47 Monoclonal Antibody) Shows Promising Antitumor Efficacy and a Favorable Safety Profile Read More »